先声药业（02096）于2026年9月2日发布翌日披露报表，公司于当日在香港联交所场内回购普通股共计1,053,000股，占回购前已发行股本约0.041%。回购价格区间介乎每股11.4711港元至11.86港元，合计支付对价约12,357,390港元，折合约1,235.74万港元。
本次回购后，先声药业的已发行股本保持在2,568,198,618股，库藏股数量为0。公司于2026年6月12日曾通过购回授权，本次回购系在相关授权下进行，公司最多可购回256,819,861股。先声药业在公告中确认已遵守香港联交所证券上市规则及相关法律法规。
本公告由先声药业联席公司秘书朱达签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.